Fluorescent Imaging of Nerves With Illuminare-1 During Surgery
Status:
Recruiting
Trial end date:
2023-10-04
Target enrollment:
Participant gender:
Summary
This study will test the safety of using Illuminare-1 during standard surgery for prostate
cancer. The study researchers will test increasing doses of Illuminare-1 to find the dose
that makes the nerve structures fluoresce (light up) but causes few or mild side effects.
When the researchers find this dose, it will be tested in new groups of study participants to
see whether surgery performed using Illuminare-1 guidance is better than surgery performed
without intraoperative guidance. The researchers will also do tests to study the way the body
absorbs, distributes, and gets rid of Illuminare-1. This study is the first to test
Illuminare-1 in people. Illuminare-1 has received Fast Track designation from the US FDA.